

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2021 November 15; 13(11): 1544-1849



EDITORIAL

- 1544** Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype
Jeong KY, Lee H

OPINION REVIEW

- 1551** New drugs for the treatment of metastatic colorectal cancer
Cherri S, Libertini M, Zaniboni A

REVIEW

- 1561** Extracellular vesicles: General features and usefulness in diagnosis and therapeutic management of colorectal cancer
Mammes A, Pasquier J, Mammes O, Conti M, Douard R, Loric S
- 1599** Radiomics in hepatocellular carcinoma: A state-of-the-art review
Yao S, Ye Z, Wei Y, Jiang HY, Song B
- 1616** Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment
Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A
- 1632** Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer
Joechle K, Guenzle J, Hellerbrand C, Strnad P, Cramer T, Neumann UP, Lang SA
- 1648** Regulatory role of the transforming growth factor- β signaling pathway in the drug resistance of gastrointestinal cancers
Lv X, Xu G

MINIREVIEWS

- 1668** Novel perspective in pancreatic cancer therapy: Targeting ferroptosis pathway
Yang Y, Zhang ZJ, Wen Y, Xiong L, Huang YP, Wang YX, Liu K
- 1680** Liver tumors in children with chronic liver diseases
Sintusek P, Phewplung T, Sanpavat A, Poovorawan Y
- 1696** Non-surgical treatment of hilar cholangiocarcinoma
Inchingolo R, Acquafredda F, Ferraro V, Laera L, Surico G, Surgo A, Fiorentino A, Marini S, de'Angelis N, Memeo R, Spiliopoulos S

ORIGINAL ARTICLE**Basic Study**

- 1709** Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis
Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ
- 1725** Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma
Deng Z, Teng YJ, Zhou Q, Ouyang ZG, Hu YX, Long HP, Hu MJ, Mei S, Lin FX, Dai XJ, Zhang BY, Feng T, Tian XF
- 1741** Preventive and inhibitive effects of Yiwei Xiaoyu granules on the development and progression of spasmolytic polypeptide-expressing metaplasia lesions
Chen WQ, Tian FL, Zhang JW, Yang XJ, Li YP
- 1755** Effects of dietary zinc deficiency on esophageal squamous cell proliferation and the mechanisms involved
Chen Y, Liu FX, Liu H

Case Control Study

- 1766** Genetic variation of TGF- β 2 as a protective genotype for the development of colorectal cancer in men
Stanilov N, Grigorova A, Velikova T, Stanilova SA

Clinical Trials Study

- 1781** Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer
Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK

SYSTEMATIC REVIEWS

- 1791** Colorectal cancer in Arab world: A systematic review
Makhlouf NA, Abdel-Gawad M, Mahros AM, Lashen SA, Zaghloul M, Eliwa A, Elshemy EE, Ali-Eldin Z, Abdeltawab D, El-Raey F, Omran D, Khalaf M, Fanous N, Abdelmohsen AS, Abu-Elfath A, Abdelghani M, Farouk M, Abdelaziz M, Alboraie M
- 1799** Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review
Uhe I, Hagen ME, Ris F, Meyer J, Toso C, Douissard J
- 1813** Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E

META-ANALYSIS

- 1833** Anatomical *vs* nonanatomical liver resection for solitary hepatocellular carcinoma: A systematic review and meta-analysis
Liu H, Hu FJ, Li H, Lan T, Wu H

LETTER TO THE EDITOR

- 1847** Hepatocellular carcinoma biomarkers, an imminent need

Zamora-León SP

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Wen-Wei Sung, MD, PhD, Associate Professor, Doctor, Surgeon, Department of Urology; School of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Taichung 40201, Taiwan. flutewayne@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Rosa M Jimenez Rodriguez, Pashtoon M Kasi, Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

November 15, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Hepatocellular carcinoma biomarkers, an imminent need

S Pilar Zamora-León

ORCID number: S Pilar Zamora-León
[0000-0002-4738-9768](https://orcid.org/0000-0002-4738-9768).

Author contributions: Zamora-León SP wrote the letter.

Conflict-of-interest statement: The author declares having no conflict of interest related to this letter.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Provenance and peer review: Invited article; Externally peer reviewed.

Specialty type: Oncology

Country/Territory of origin: Chile

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0

S Pilar Zamora-León, Department of Preclinical Sciences, Faculty of Medicine, Universidad Católica del Maule, Talca 3460000, Chile

Corresponding author: S Pilar Zamora-León, MSc, PhD, Academic Research, Assistant Professor, Department of Preclinical Sciences, Faculty of Medicine, Universidad Católica del Maule, Avenida San Miguel 3605, Talca 3460000, Chile. pzamora@ucm.cl

Abstract

Hepatocellular carcinoma (HCC) is the most common malignant neoplasm of the liver and one of the deadliest cancers worldwide. The identification of novel, highly specific and more sensitive biomarkers for HCC is crucial because existing ones are deficient and non-confirmatory without histological biopsy or imaging techniques.

Key Words: Hepatocellular carcinoma; Biomarker; Blood; Urine; Feces; Gut microbiota

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The identification of specific, sensitive and validated biomarkers for hepatocellular carcinoma (HCC) is complex because of the variability in genetic profiles, but their requirement is urgent to achieve earlier detection of HCC. Body fluids and feces for biomarker detection constitute feasible and low cost screening tools for early diagnosis, prognosis and treatment of HCC.

Citation: Zamora-León SP. Hepatocellular carcinoma biomarkers, an imminent need. *World J Gastrointest Oncol* 2021; 13(11): 1847-1849

URL: <https://www.wjgnet.com/1948-5204/full/v13/i11/1847.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v13.i11.1847>

TO THE EDITOR

I read the review by Guan *et al* [1], "Biomarkers for hepatocellular carcinoma based on body fluids and feces", published in the April 2021 issue of the *World Journal of Gastrointestinal Oncology*, with profound interest.

Grade E (Poor): 0

Received: May 25, 2021**Peer-review started:** May 25, 2021**First decision:** July 4, 2021**Revised:** July 5, 2021**Accepted:** September 19, 2021**Article in press:** September 19, 2021**Published online:** November 15, 2021**P-Reviewer:** Tajiri K**S-Editor:** Gao CC**L-Editor:** A**P-Editor:** Li X

Hepatocellular carcinoma (HCC) is the leading malignant neoplasm of the liver and one of the most common lethal cancers worldwide. For this reason, an early detection is crucial to decrease mortality, since symptomatology appears at later stages of the disease. The identification of novel, highly specific and sensitive biomarkers, or a combination of them, is of special concern because the existing ones are deficient and non-confirmatory without histological biopsy or imaging techniques. The utilization of body fluids and feces for biomarker detection constitutes a feasible minimally- or non-invasive and low-cost screening method that facilitates studies for early diagnosis, prognosis and treatment of HCC.

Since HCC can arise from a variety of etiological factors, such as metabolic disorders, virus infections or toxin exposure, the genetic profiles are considerably variable, resulting in diverse hepatic immune microenvironments. This implies that the metabolomic, proteomic and glycomic profiles should be better clarified for the various HCCs in order to improve overall understanding of the disease and allow for identification of appropriate and validated biomarkers[2].

Alpha-fetoprotein (AFP) is the most common biomarker utilized for HCC diagnosis, but its sensitivity is only 39%-65% and its performance at early stages of the disease is suboptimal. Therefore, to improve detection of the malignancy, AFP has to be combined with imaging findings as well as other parameters, such as age and sex, which increase the sensitivity. In addition, AFP-L3, the highest glycoform of AFP, has exhibited much higher sensitivity, and the AFP-L3/AFP ratio can be considered as a risk factor for the development of HCC[3].

Several metabolites have displayed higher accuracy than AFP, showing aberrant levels that can be detected at earlier stages of HCC[4]. Circulating tumor (ct)DNA also has great potential to become a biomarker, since it contains several tumor-specific mutations or epimutations, constituting a good approach for HCC detection and prognosis, and to serve as a tool for monitoring therapeutic response. Additionally, several different micro (mi)RNAs and other non-coding (nc)RNAs have been shown to be deregulated in HCC, implying that their aberrant expression should be evaluated and validated as potential prognostic biomarkers. Unfortunately, miRNA variabilities have been detected depending on whether they are measured in serum or plasma, thereby complicating interpretation[5-8].

Moreover, circulating tumor cells (CTCs) have shown partial sensitivity but high specificity and are considered to have great potential in prediction of recurrence and prognostic evaluation of HCC. On the other hand, extracellular vesicles (EVs), such as exosomes and microvesicles, the contents of which are very heterogeneous, do not present better diagnostic performances than CTCs or circulating cell-free DNA, but they do have good potential as future therapeutic agents[5,8,9].

The above-mentioned biomarkers, ctDNA, miRNAs, CTCs and EVs, are tumor-specific, which is of great advantage, because they exhibit the heterogeneity of the tumor and its evolution. These features cannot be detected with other plasma biomarkers.

Additionally, several urine molecules have the potential to be classified as biomarkers for prevention, detection, progression monitoring, and recurrence prediction of HCC[10]. It is possible that they can be used as auxiliary diagnostic tools in combination with AFP. Moreover, feces-based biomarkers, which reflect the gut microbiota — which is itself known to vary with different pathological stages, are under evaluation for their potential utility in early diagnosis, prognosis and progression monitoring of HCC. In addition, the use of antibiotics to modulate gut microbiota appears to be a favorable strategy to influence the progression of HCC. Promising results have also been obtained with probiotics in mouse HCC models, which have shown a reduction in the development of this malignant neoplasm, opening avenues of possible application as a therapy in humans in the future[11-13].

The identification of more specific and sensitive biomarkers for HCC, and their variability over time, is an urgent requirement due to their critical role for early detection and prognosis, for choosing appropriate therapy, or for use as a tool to follow-up the patient's treatment response. Ideally, biomarkers should detect HCC months before the tumor is visible, to improve surveillance and facilitate initiation of an earlier therapy. Clearly, the identification of new biomarkers for prompt HCC detection is complex, nonetheless because of the diverse type of tumors (genetic heterogeneity). However, efforts must be made to combat this devastating tumor malignancy. Moreover, the performance of new biomarkers will have to be clinically validated to optimize the current therapeutic strategies.

ACKNOWLEDGEMENTS

I would like to thank the Faculty of Medicine and Universidad Católica del Maule for giving me the time to write this letter.

REFERENCES

- 1 **Guan MC**, Ouyang W, Wang MD, Liang L, Li N, Fu TT, Shen F, Lau WY, Xu QR, Huang DS, Zhu H, Yang T. Biomarkers for hepatocellular carcinoma based on body fluids and feces. *World J Gastrointest Oncol* 2021; **13**: 351-365 [PMID: [34040698](#) DOI: [10.4251/wjgo.v13.i5.351](#)]
- 2 **Duan J**, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine. *J Hepatocell Carcinoma* 2019; **6**: 151-166 [PMID: [31696097](#) DOI: [10.2147/JHC.S224849](#)]
- 3 **Daniele B**, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S108-S112 [PMID: [15508073](#) DOI: [10.1053/j.gastro.2004.09.023](#)]
- 4 **Kim DJ**, Cho EJ, Yu KS, Jang IJ, Yoon JH, Park T, Cho JY. Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis. *Cancers (Basel)* 2019; **11** [PMID: [31590436](#) DOI: [10.3390/cancers11101497](#)]
- 5 **Singh G**, Yoshida EM, Rath S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. *World J Hepatol* 2020; **12**: 558-573 [PMID: [33033565](#) DOI: [10.4254/wjh.v12.i9.558](#)]
- 6 **Beudeker BJB**, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. *Therap Adv Gastroenterol* 2020; **13**: 1756284820931734 [PMID: [32647536](#) DOI: [10.1177/1756284820931734](#)]
- 7 **De Stefano F**, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. *Dig Liver Dis* 2018; **50**: 1115-1123 [PMID: [30217732](#) DOI: [10.1016/j.dld.2018.08.019](#)]
- 8 **Piñero F**, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. *Cells* 2020; **9** [PMID: [32492896](#) DOI: [10.3390/cells9061370](#)]
- 9 **Chen W**, Mao Y, Liu C, Wu H, Chen S. Exosome in Hepatocellular Carcinoma: an update. *J Cancer* 2021; **12**: 2526-2536 [PMID: [33854614](#) DOI: [10.7150/jca.54566](#)]
- 10 **Zhao Y**, Li Y, Liu W, Xing S, Wang D, Chen J, Sun L, Mu J, Xing B, Sun W, He F. Identification of noninvasive diagnostic biomarkers for hepatocellular carcinoma by urinary proteomics. *J Proteomics* 2020; **225**: 103780 [PMID: [32298775](#) DOI: [10.1016/j.jpro.2020.103780](#)]
- 11 **Ren Z**, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, Xu S, Zhang H, Cui G, Sun R, Wen H, Lerut JP, Kan Q, Li L, Zheng S. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. *Gut* 2019; **68**: 1014-1023 [PMID: [30045880](#) DOI: [10.1136/gutjnl-2017-315084](#)]
- 12 **Rattan P**, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. *Liver Transpl* 2020; **26**: 1316-1327 [PMID: [32564483](#) DOI: [10.1002/lt.25828](#)]
- 13 **Li E**, Lin L, Chen CW, Ou DL. Mouse Models for Immunotherapy in Hepatocellular Carcinoma. *Cancers (Basel)* 2019; **11** [PMID: [31731753](#) DOI: [10.3390/cancers11111800](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

